At a glance
ClinicalIndex Comparison RecordN/ACompleted· 18,223 enrolled
Drug / intervention
Pioglitazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Actos Tablets Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"
In Brief
An observational study evaluating Pioglitazone for Type 2 Diabetes Mellitus. Completed, enrolled 18,223 participants.
Detailed Summary
The purpose of this survey is to determine the onset of new cerebral and cardiovascular events and changes in metabolic syndrome parameters in patients with type 2 diabetes mellitus on long-term pioglitazone (Actos Tablets) treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
Primary CompletionJun 2013
First PostedDec 2013
TodayJul 2026
First PostedDec 6, 2013
Enrollment StartOct 16, 2007
Primary CompletionJun 30, 2013
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 12.6 years ago
Interventions
Pioglitazonedrug
Pioglitazone tablets